<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01757041</url>
  </required_header>
  <id_info>
    <org_study_id>B9RUHL0</org_study_id>
    <nct_id>NCT01757041</nct_id>
  </id_info>
  <brief_title>The Clinical and Molecular Epidemiology of Streptococcus Agalactiae Colonisation on the Kenyan Coast</brief_title>
  <acronym>GBS</acronym>
  <official_title>The Clinical and Molecular Epidemiology of Streptococcus Agalactiae (Group B Streptococcus)Maternal Colonisation and Association With Adverse Perinatal Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sub-Saharan Africa (sSA) has the highest regional rates of perinatal mortality worldwide.&#xD;
      Group B Streptococcus (GBS) has been identified as a leading cause of early onset neonatal&#xD;
      sepsis (EOS, in &lt;7 days of life) in sSA. In other regions, maternal carriage is associated&#xD;
      with early onset neonatal sepsis, but in addition, other adverse perinatal outcomes&#xD;
      (stillbirths, early neonatal death, low birth weight and prematurity). Robust data on&#xD;
      maternal GBS carriage in sSA and its burden on adverse perinatal outcomes are lacking, with&#xD;
      important consequences for public health interventions.&#xD;
&#xD;
      Through investigation of maternal carriage and perinatal outcomes at three different sites:&#xD;
      rural, semi-rural and urban, this study will provide a comprehensive description of the&#xD;
      burden of GBS in coastal Kenya, informing public health policy and driving forward&#xD;
      interventions. Risk factors for maternal colonisation and invasive neonatal disease will be&#xD;
      assessed, including through retrospective immunological investigation of cord blood in&#xD;
      neonates subsequently identified as having invasive GBS disease or other adverse perinatal&#xD;
      outcomes, compared to those without.&#xD;
&#xD;
      GBS isolates from maternal colonisation will be typed (sero-typing and molecular analysis),&#xD;
      and these isolates will be compared to existing archived neonatal isolates from investigation&#xD;
      of neonatal sepsis in KDH (Kilifi District Hospital). This is important so that we know the&#xD;
      prevalent sub-types causing neonatal disease in Kenya, those which are carried by mothers,&#xD;
      and therefore whether maternal GBS carriage correlates with a high risk of perinatal disease.&#xD;
      GBS vaccines in development are type-specific and this will inform their use in sSA.&#xD;
&#xD;
      Stillbirths will also be investigated, in individual cases, through additional detailed&#xD;
      microbiological and other laboratory investigations to make an assessment of the contribution&#xD;
      of GBS to stillbirths in Kenya.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Maternal recto-vaginal GBS colonisation</measure>
    <time_frame>Single time point (at delivery)</time_frame>
    <description>Prevalence of GBS recto-vaginal carriage in pregnant mothers in rural, semi-rural and urban sites.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stillbirths</measure>
    <time_frame>Single time point (at delivery)</time_frame>
    <description>Association of stillbirth with Group B Streptococcus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal GBS Colonisation</measure>
    <time_frame>Within 4h of delivery</time_frame>
    <description>Prevalence of neonatal GBS colonization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm birth</measure>
    <time_frame>Single time point (at delivery)</time_frame>
    <description>Determine association between GBS and preterm birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low birth weight</measure>
    <time_frame>Single time point (at delivery)</time_frame>
    <description>Association of GBS with low birth weight babies</description>
  </secondary_outcome>
  <enrollment type="Actual">7967</enrollment>
  <condition>Streptococcus Agalactiae (Streptococcus Group B)</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Mothers admitted for delivery to participating health centres (Kilifi District Hospital,&#xD;
        Coast Provincial General Hospital, Bamba sub-District Hospital, Ganze Health Facility).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Admitted for delivery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Consent refusal&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Seale, BMBCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>KEMRI-Wellcome Trust and University of Oxford</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bamba sub-District Hospital</name>
      <address>
        <city>Bamba</city>
        <state>Coast</state>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ganze Health Facility</name>
      <address>
        <city>Ganze</city>
        <state>Coast</state>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kilifi District Hospital</name>
      <address>
        <city>Kilifi</city>
        <state>Coast</state>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coast Provincial General Hospital</name>
      <address>
        <city>Mombasa</city>
        <state>Coast</state>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>November 28, 2012</study_first_submitted>
  <study_first_submitted_qc>December 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2012</study_first_posted>
  <last_update_submitted>December 18, 2014</last_update_submitted>
  <last_update_submitted_qc>December 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Streptococcus agalactiae</keyword>
  <keyword>Maternal</keyword>
  <keyword>Newborn</keyword>
  <keyword>Africa</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

